Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the
pyruvate kinase enzyme. Mitapivat has been shown to significantly upregulate both wild …

Red cell pyruvate kinase (PK) deficiency is the most common glycolytic defect associated
with congenital non-spherocytic hemolytic anemia. The disease, transmitted as an …

Background Pyruvate kinase deficiency is a rare, hereditary, chronic condition that is
associated with hemolytic anemia. In a phase 2 study, mitapivat, an oral, first-in-class …

Mutations in the PKLR gene lead to pyruvate kinase (PK) deficiency, causing chronic
hemolytic anemia secondary to reduced red cell energy, which is crucial for maintenance of …

Pyruvate kinase deficiency (PKD) is the most common cause of congenital nonspherocytic
hemolytic anemia. Although recognition of the disease spectrum has recently expanded …

This study aimed to identify baseline metabolic biomarkers for response to methotrexate
(MTX) therapy in rheumatoid arthritis (RA) using an untargeted method. In total, 82 baseline …

Hemoglobin S (HbS) polymerization, red blood cell (RBC) sickling, chronic anemia, and
vaso-occlusion are core to sickle cell disease (SCD) pathophysiology. Pyruvate kinase (PK) …

Mitapivat (Pyrukynd®), an oral, allosteric activator of pyruvate kinase (PK), is approved in the
USA for the treatment of haemolytic anaemia in adults with PK deficiency and in the EU and …

Diagnosis of pyruvate kinase deficiency (PKD), the most common cause of hereditary non‐
spherocytic haemolytic anaemia, remains challenging in routine practice and no biomarkers …

Background and Objectives: To evaluate the clinical findings of glucose 6-phosphate
dehydrogenase (G6PD) and pyruvate kinase (PK) deficiency in prolonged jaundice and to …